ATE78162T1 - 5-ht3-rezeptor-antagonisten zur behandlung von husten und bronchokonstriktion. - Google Patents

5-ht3-rezeptor-antagonisten zur behandlung von husten und bronchokonstriktion.

Info

Publication number
ATE78162T1
ATE78162T1 AT88909596T AT88909596T ATE78162T1 AT E78162 T1 ATE78162 T1 AT E78162T1 AT 88909596 T AT88909596 T AT 88909596T AT 88909596 T AT88909596 T AT 88909596T AT E78162 T1 ATE78162 T1 AT E78162T1
Authority
AT
Austria
Prior art keywords
treatment
bronchoconstriction
cough
pct
receptor antagonists
Prior art date
Application number
AT88909596T
Other languages
English (en)
Inventor
Andrew James Beecham Williams
Road Bottom
Original Assignee
Beecham Group Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB878726717A external-priority patent/GB8726717D0/en
Priority claimed from GB878726716A external-priority patent/GB8726716D0/en
Application filed by Beecham Group Plc filed Critical Beecham Group Plc
Application granted granted Critical
Publication of ATE78162T1 publication Critical patent/ATE78162T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Electrotherapy Devices (AREA)
  • Conductive Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Indole Compounds (AREA)
AT88909596T 1987-11-14 1988-11-14 5-ht3-rezeptor-antagonisten zur behandlung von husten und bronchokonstriktion. ATE78162T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB878726717A GB8726717D0 (en) 1987-11-14 1987-11-14 Treatment
GB878726716A GB8726716D0 (en) 1987-11-14 1987-11-14 Treatment
EP88909596A EP0340270B1 (de) 1987-11-14 1988-11-14 5-ht3-rezeptor-antagonisten zur behandlung von husten und bronchokonstriktion
PCT/GB1988/000994 WO1989004660A1 (en) 1987-11-14 1988-11-14 5-ht3 receptor antagonists for treatment of cough and bronchoconstriction

Publications (1)

Publication Number Publication Date
ATE78162T1 true ATE78162T1 (de) 1992-08-15

Family

ID=26293045

Family Applications (1)

Application Number Title Priority Date Filing Date
AT88909596T ATE78162T1 (de) 1987-11-14 1988-11-14 5-ht3-rezeptor-antagonisten zur behandlung von husten und bronchokonstriktion.

Country Status (9)

Country Link
US (1) US5098909A (de)
EP (1) EP0340270B1 (de)
JP (1) JPH02502185A (de)
KR (1) KR890701099A (de)
AT (1) ATE78162T1 (de)
AU (1) AU616706B2 (de)
DE (1) DE3872872T2 (de)
DK (1) DK345889A (de)
WO (1) WO1989004660A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8072691A (en) * 1990-06-28 1992-01-23 Beecham Group Plc Pharmaceutical preparations
HU211081B (en) * 1990-12-18 1995-10-30 Sandoz Ag Process for producing indole derivatives as serotonin antagonists and pharmaceutical compositions containing the same
CA2112487C (en) * 1991-06-26 2003-04-15 James W. Young Method and compositions for treating emesis, nausea and other disorders using optically pure r(+) ondansetron
WO2000051582A2 (en) 1999-03-01 2000-09-08 Sepracor Inc. Methods for treating apnea and apnea disorders using optically pure r(+)ondansetron
CN1355698A (zh) * 1999-06-15 2002-06-26 呼吸器有限公司 可用作治疗有关支气管收缩的机能障碍的药物的化合物
GB9918425D0 (en) * 1999-08-04 1999-10-06 Novartis Ag Organic compounds
WO2001095903A1 (en) * 2000-06-15 2001-12-20 Respiratorius Ab 5-ht3 receptor antagonists for treatment of disorders involving airway constriction
AU2003276919B2 (en) * 2002-09-25 2013-05-16 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof
WO2004091606A1 (en) * 2003-04-16 2004-10-28 Orchid Chemicals & Pharmaceuticals, Ltd. Treatment of bronchial asthma using 5-ht3 receptor antagonists
DE602004010299T2 (de) * 2003-12-22 2008-09-18 Memory Pharmaceuticals Corp. Indole, 1h-indazole, 1,2-benzisoxazole und 1,2-benzisothiazole und deren herstellung und anwendungen
RU2417225C2 (ru) 2004-03-25 2011-04-27 Мемори Фармасьютиклз Корпорейшн Индазолы, бензотиазолы, бензоизотиазолы, бензизоксазолы и их получение и применение
JP2007534692A (ja) * 2004-04-22 2007-11-29 メモリー・ファーマシューティカルズ・コーポレイション インドール、１ｈ−インダゾール、１，２−ベンズイソキサゾール、１，２−ベンゾイソチアゾール、ならびにその調製および使用
JP2007538011A (ja) * 2004-05-07 2007-12-27 メモリー・ファーマシューティカルズ・コーポレイション １ｈ−インダゾール、ベンゾチアゾール、１，２−ベンゾイソキサゾール、１，２−ベンゾイソチアゾール、およびクロモン、ならびにそれらの調製および使用
BRPI0517494A (pt) * 2004-12-22 2008-10-14 Memory Pharm Corp composto, composição farmacêutica, método de ativação/estimulação seletiva de receptores nicotìnicos de a-7 em um paciente em que tal ativação/estimulação tem um efeito terapêutico, método de tratamento de um paciente que sofre de uma doença psicótica, uma doença neurodegenerativa que envolve uma disfunção do sistema colinérgico, e/ou uma condição de debilitação da memória e/ou da cognição, método de tratamento de um paciente que sofre de demência e/ou uma outra condição com perda da memória, método de tratamento de um paciente que sofre de debilitação da memória devido à debilitação cognitiva suave devido ao envelhecimento, mal de alzheimer, esquizofrenia, mal de parkinson, mal de huntington, mal de pick, mal de creutzfeldt-jakob, depressão, envelhecimento, trauma na cabeça, acidente vascular cerebral, hipoxia do snc, senilidade cerebral, demência de multiinfarto, hiv e/ou doença cardiovascular, método de tratamento e/ou prevenção da demência em um paciente com o mal de alzheimer, método de tratamento de um paciente para cortar o vìcio do álcool ou o tratamento de um paciente com a terapia anti-intoxicação, método de tratamento de um paciente para propiciar neuroproteção contra os danos associados com acidentes vasculares cerebrais e isquemia e excitotoxicidade induzida por glutamatos, método de tratamento de um paciente que sofre do vìcio da nicotina, dor, tontura do fuso horário, obesidade e/ou diabetes, método de indução do ato de parar fumar em um paciente, método de tratamento de um paciente que sofre de debilitação cognitiva suave (mci), demência vascular (vad), declìnio cognitivo associado com a idade (aacd), amnésia associada com a cirurgia com o coração aberto, parada cardìaca, anestesia geral, deficiências da memória devido à exposição a agentes anestésicos, debilitação cognitiva induzida pela privação do sono, sìndrome de fadiga crÈnica, narcolepsia, demência relacionada com a aids, debilitação cognitiva relacionada com a epilepsia, sìndrome de down, demência relacionada ao alcoolismo, debilitações da memória induzidas por drogas/substáncias, demência pugilìstica (sìndrome do boxeador), ou demência animal, método para o tratamento da perda da memória, método para o tratamento de um paciente que sofre de debilitação da memória, método para o tratamento ou a profilaxia de uma doença ou de uma condição resultante da disfunção da transmissão do receptor nicotìnico de acetilcolina em um paciente, método para o tratamento ou a profilaxia de uma doença ou de uma condição resultante de receptores nicotìnicos de acetilcolina defeituosos ou funcionando mal em um paciente, método para o tratamento ou a profilaxia de uma doença ou de uma condição resultante da transmissão suprimida do receptor nicotìnico de acetilcolina em um paciente, método para o tratamento ou a profilaxia de uma doença ou de uma condição resultante da perda de sinapses colinérgicas em um paciente, método para a proteção dos neurÈnios em um paciente com neurotoxicidade induzi
US8106066B2 (en) * 2005-09-23 2012-01-31 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3650772T2 (de) * 1985-04-27 2003-04-03 F. Hoffmann-La Roche Ag, Basel Derivate von Indazole-3-carboxamide und -3-carboxylsäure

Also Published As

Publication number Publication date
JPH02502185A (ja) 1990-07-19
KR890701099A (ko) 1989-12-19
DK345889D0 (da) 1989-07-12
AU616706B2 (en) 1991-11-07
DE3872872T2 (de) 1993-02-04
DK345889A (da) 1989-07-12
WO1989004660A1 (en) 1989-06-01
US5098909A (en) 1992-03-24
AU2626488A (en) 1989-06-14
EP0340270A1 (de) 1989-11-08
EP0340270B1 (de) 1992-07-15
DE3872872D1 (de) 1992-08-20

Similar Documents

Publication Publication Date Title
DE3872872D1 (de) 5-ht3-rezeptor-antagonisten zur behandlung von husten und bronchokonstriktion.
DK46789D0 (da) 3-indolpyrodruesyrederivater og farmaceutisk anvendelse deraf
DE69925024D1 (de) Verwendung von eph-rezeptor-antagonisten und agonisten zur behandlung von vaskulären krankheiten
PT98710A (pt) Processo de preparacao de compostos de indolilo substituidos e de composicoes farmaceuticas que os contem
DE69528475D1 (de) Verwendung von serotonin-antagonisten (5ht3) zur behandlung von fibromyalgie
ATE198830T1 (de) Verwendung von nikotinanalogen zur behandlung von degenerativen erkrankungen des nervensystems
NO2015027I1 (no) Mepolizumab
DE69805973D1 (de) Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin-abhängigen protein kinase
DE69017302D1 (de) Zentrale Cholecystokinin-Antagonisten zur Behandlung von psychiatrischen Krankheiten.
DE3650647D1 (de) Arzneimittel zur Behandlung von Anxietas
IL83687A0 (de)
PT83535A (de) Verfahren zur behandlung von atherosklerose thrombose und der peripheren gefaesskrankheit
DE69316013D1 (de) Verwendung von phosphinate zur behandlung der osteoporose
ATE224719T1 (de) Phosphatidsäure enthaltende zusammensetzungen
BR9508406A (pt) Uso de um composto e método para o tratamento e/ou profilaxia em mamíferos
ATE127021T1 (de) Immunstimulierendes arzneimittel, das polare glycopeptidolipide von mycobakterium-chelonae enthält.
DE69207698D1 (de) Arylalkylester der 4,5-dihydoxy-9,10-dihydro-9,10-dioxo-2-anthracencarbonsäure und deren therapeutische verwendung
DE69023006D1 (de) Verfahren zur behandlung von thrombocytopenie und dafür geeignete pharmazeutische zusammensetzungen.
ATE222768T1 (de) Ctla-8 in kombination mit g-csf oder mit g-csf und il-6, und verwendung vom ctla-8 zur behandlung von infektionen
OA08298A (fr) Nouvelles N-(aminométhyl-5 oxazolin-2 yl-2) N'-phénylurées, leur méthode de préparation ainsi que leur application thérapeutique.
ATE80998T1 (de) Verwendung von nalmefen zur herstellung eines arzneimittels zur behandlung der schaedigung des zentralnervensystems.
ATE221068T1 (de) Anellierte beta-carboline
DD234236A1 (de) Vorrichtung zur abscheidung und thermischen behandlung von feinkoernigem gut
ATE95061T1 (de) Schmiermittelzubereitung zur behandlung von rheuma.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee